Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that differentially regulates tissue homeostasis and disease pathogenesis. In physiological contexts, it maintains melanosome biogenesis, osteogenesis, and neuroprotection through domain-specific interactions. Pathologically, tumors exploit GPNMB’s dual mechanisms: membrane-bound isoforms mediate T cell exclusion via DC-HIL/Syndecan-4, while soluble GPNMB(sGPNMB) promote metabolic reprogramming through CD44/NF-κB. Clinically, GPNMB overexpression correlates with poor outcomes, notably demonstrating 40% versus 8% ADC response in high- versus low-expressing TNBC (p 0.001). Emerging data reveal its crosstalk with HER2/FGFR1 pathways and identify K48-ubiquitination as a therapeutic resistance mechanism. These findings position domain-selective GPNMB targeting as a promising precision oncology strategy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Cheng Long
Yun Li
Yuan Ma
Frontiers in Molecular Biosciences
Building similarity graph...
Analyzing shared references across papers
Loading...
Long et al. (Fri,) studied this question.
www.synapsesocial.com/papers/68f43f09854d1061a58ac6b3 — DOI: https://doi.org/10.3389/fmolb.2025.1664764
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: